ZBH Stock Overview
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates in the musculoskeletal healthcare business in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.
Zimmer Biomet Holdings Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$120.65|
|52 Week High||US$169.98|
|52 Week Low||US$108.47|
|1 Month Change||-2.82%|
|3 Month Change||-4.78%|
|1 Year Change||-28.03%|
|3 Year Change||6.87%|
|5 Year Change||-1.65%|
|Change since IPO||305.41%|
Recent News & Updates
Zimmer Biomet Is Hobbling Behind The Market
Zimmer Biomet has greatly underperformed the S&P 500 as well as the iShares IHI, been stagnant over the past 5 years. The street consensus gives some hope for the projected growth with an estimated 28.67% FCF and 7.19% EBIT CAGR over the next 5 years. Zimmer Biomet carries noteworthy risks and faces significant challenges while its peers perform much better with an advantageous risk-reward profile. Based on my valuation model, the stock is fairly priced with a slightly higher price target at $139.
|ZBH||US Medical Equipment||US Market|
Return vs Industry: ZBH underperformed the US Medical Equipment industry which returned -15.8% over the past year.
Return vs Market: ZBH underperformed the US Market which returned -15.1% over the past year.
|ZBH Average Weekly Movement||4.4%|
|Medical Equipment Industry Average Movement||10.5%|
|Market Average Movement||7.8%|
|10% most volatile stocks in US Market||16.8%|
|10% least volatile stocks in US Market||2.9%|
Stable Share Price: ZBH is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: ZBH's weekly volatility (4%) has been stable over the past year.
About the Company
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates in the musculoskeletal healthcare business in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company designs, manufactures, and markets orthopaedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest toss facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products, as well as robotic, surgical and bone cement products.
Zimmer Biomet Holdings Fundamentals Summary
|ZBH fundamental statistics|
Is ZBH overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ZBH income statement (TTM)|
|Cost of Revenue||US$2.36b|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||1.34|
|Net Profit Margin||3.56%|
How did ZBH perform over the long term?See historical performance and comparison
0.8%Current Dividend Yield
Does ZBH pay a reliable dividends?See ZBH dividend history and benchmarks
|Zimmer Biomet Holdings dividend dates|
|Ex Dividend Date||Jun 24 2022|
|Dividend Pay Date||Jul 29 2022|
|Days until Ex dividend||28 days|
|Days until Dividend pay date||63 days|
Does ZBH pay a reliable dividends?See ZBH dividend history and benchmarks
Is Zimmer Biomet Holdings undervalued compared to its fair value and its price relative to the market?
Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: ZBH ($120.65) is trading below our estimate of fair value ($180.03)
Significantly Below Fair Value: ZBH is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: ZBH is poor value based on its Price-To-Earnings Ratio (89.9x) compared to the US Medical Equipment industry average (35.2x).
PE vs Market: ZBH is poor value based on its Price-To-Earnings Ratio (89.9x) compared to the US market (15.2x).
Price to Earnings Growth Ratio
PEG Ratio: ZBH is poor value based on its PEG Ratio (5.2x)
Price to Book Ratio
PB vs Industry: ZBH is good value based on its Price-To-Book Ratio (2.1x) compared to the US Medical Equipment industry average (2.5x).
How is Zimmer Biomet Holdings forecast to perform in the next 1 to 3 years based on estimates from 24 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ZBH's forecast earnings growth (17.4% per year) is above the savings rate (1.9%).
Earnings vs Market: ZBH's earnings (17.4% per year) are forecast to grow faster than the US market (13% per year).
High Growth Earnings: ZBH's earnings are forecast to grow, but not significantly.
Revenue vs Market: ZBH's revenue (3.6% per year) is forecast to grow slower than the US market (8% per year).
High Growth Revenue: ZBH's revenue (3.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ZBH's Return on Equity is forecast to be low in 3 years time (10.9%).
How has Zimmer Biomet Holdings performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ZBH has a large one-off loss of $729.8M impacting its March 31 2022 financial results.
Growing Profit Margin: ZBH's current net profit margins (3.6%) are lower than last year (8.2%).
Past Earnings Growth Analysis
Earnings Trend: ZBH's earnings have declined by 21.7% per year over the past 5 years.
Accelerating Growth: ZBH's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: ZBH had negative earnings growth (-50.1%) over the past year, making it difficult to compare to the Medical Equipment industry average (16.1%).
Return on Equity
High ROE: ZBH's Return on Equity (2.3%) is considered low.
How is Zimmer Biomet Holdings's financial position?
Financial Health Score4/6
Financial Health Score 4/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: ZBH's short term assets ($4.5B) exceed its short term liabilities ($2.7B).
Long Term Liabilities: ZBH's short term assets ($4.5B) do not cover its long term liabilities ($6.9B).
Debt to Equity History and Analysis
Debt Level: ZBH's net debt to equity ratio (49.3%) is considered high.
Reducing Debt: ZBH's debt to equity ratio has reduced from 115.8% to 53.1% over the past 5 years.
Debt Coverage: ZBH's debt is well covered by operating cash flow (23.3%).
Interest Coverage: ZBH's interest payments on its debt are well covered by EBIT (6.6x coverage).
What is Zimmer Biomet Holdings's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Current Dividend Yield
Upcoming Dividend Payment
Dividend Yield vs Market
Notable Dividend: ZBH's dividend (0.8%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.54%).
High Dividend: ZBH's dividend (0.8%) is low compared to the top 25% of dividend payers in the US market (4.01%).
Stability and Growth of Payments
Stable Dividend: ZBH is not paying a notable dividend for the US market, therefore no need to check if payments are stable.
Growing Dividend: ZBH is not paying a notable dividend for the US market, therefore no need to check if payments are increasing.
Earnings Payout to Shareholders
Earnings Coverage: ZBH is not paying a notable dividend for the US market.
Cash Payout to Shareholders
Cash Flow Coverage: ZBH is not paying a notable dividend for the US market.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Bryan Hanson (54 yo)
Mr. Bryan C. Hanson has been President, Chief Executive Officer and a Director of Zimmer Biomet Holdings, Inc. since December 19, 2017. He has been Chairman of Zimmer Biomet Holdings, Inc. since May 13, 20...
CEO Compensation Analysis
Compensation vs Market: Bryan's total compensation ($USD14.98M) is about average for companies of similar size in the US market ($USD13.20M).
Compensation vs Earnings: Bryan's compensation has been consistent with company performance over the past year.
Experienced Management: ZBH's management team is considered experienced (2.8 years average tenure).
Experienced Board: ZBH's board of directors are considered experienced (7.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Zimmer Biomet Holdings, Inc.'s employee growth, exchange listings and data sources
- Name: Zimmer Biomet Holdings, Inc.
- Ticker: ZBH
- Exchange: NYSE
- Founded: 1927
- Industry: Health Care Equipment
- Sector: Healthcare
- Implied Market Cap: US$25.286b
- Shares outstanding: 209.58m
- Website: https://www.zimmerbiomet.com
Number of Employees
- Zimmer Biomet Holdings, Inc.
- 345 East Main Street
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/26 00:00|
|End of Day Share Price||2022/05/26 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.